ECONOMIC EVALUATION OF THE ATORVASTATIN VERSUS REVASCULARIZATION TREATMENT STUDY (AVERT)- AN ITALIAN CUSTOMIZATION
Author(s)
Ruffo P1, Campanella S2, Bustacchini S1, Mantovani LG2, 1Pfizer Italia S.r.l, Rome, Italy; 2Universita' degli Studi di Milano, Milan, Italy
Presentation Documents
OBJECTIVES: Percutaneous transluminal coronary angioplasty (PTCA) is a common procedure in clinical practice with more than 50,000 procedures performed per year in Italy. There is evidence that aggressive lipid lowering therapy reduces cardiovascular events, including revascularization procedures. The objective of this analysis is to evaluate the pharmacoeconomic profile of aggressive treatment with Atorvastatin compared to PTCA in patients with PTCA indication, based on the results of the AVERT study (Pitt et al. NEJM 1999). METHODS: Technique: Cost-effectiveness analysis. Using 2 hypothetical cohorts of 1000 subjects, an incremental cost per patient free from event has been calculated. Treatments: Atorvastatin (80 mg/day) vs PTCA. Perspective: National Health Service (NHS). Timeframe: 18 months. Costs: Drugs and direct medical costs quantified by using NHS tariffs expressed in Euro 2002. Effects: Cardiac death, non-fatal acute myocardial infarction (AMI), coronary artery bypass grafting (CABG), PTCA and angina. RESULTS: The cost of aggressive Atorvastatin therapy for 1000 subjects was €5.45 million vs €8.08 million for the PTCA group. Aggressive Atorvastatin therapy was more effective than PTCA with 75 additional event free patients per 1000 treated. Safety profiles were similar in both treatment groups with a comparable incidence of adverse events. CONCLUSIONS: This economic evaluation of the AVERT study shows that aggressive Atorvastatin therapy dominates PTCA, allowing a greater number of patients to remain free of cardiovascular events at a lower cost.
Conference/Value in Health Info
2002-11, ISPOR Europe 2002, Rotterdam, The Netherlands
Value in Health, Vol. 5, No. 6 (November/December 2002)
Code
PCV7
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Cardiovascular Disorders